Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
One purpose of this study is to determine if taking droxidopa after eating will have an
effect on how the body processes (absorbs and eliminates) the drug in healthy elderly
subjects. Another purpose of this study is to see how the body processes (absorbs and
eliminates) one 300mg capsule compared to three 100mg capsules. This study will also evaluate
how well the body processes (absorbs and eliminates) and tolerates droxidopa when a 300 mg
capsule is given 3 times a day for a total dose of 900 mg over the course of one day.
Droxidopa is used to treat low blood pressure upon standing in patients with diseases of the
nervous system, to prevent low blood pressure in patients with kidney disease during
hemodialysis (removal of waste products of the blood), and to treat frozen gait (walking,
stepping or running) and dizziness upon standing in patients with Parkinson's disease.